Prostate Cancer

1. Clinical Overview

Prostate cancer represents the most common non-cutaneous malignancy in men worldwide, with an estimated 1.4 million new cases diagnosed annually and accounting for approximately 15% of all male cancers. [1] It originates from the glandular epithelium of the prostate gland, most commonly arising in the peripheral zone (70% of cases). The disease spectrum ranges from indolent, clinically insignificant tumors that may never cause symptoms to aggressive, metastatic cancers with significant morbidity and mortality. [2]

The natural history is highly variable. Many men harbor low-grade disease that remains asymptomatic throughout life (autopsy studies show 30-40% prevalence in men over 50), while others develop aggressive disease requiring multimodal therapy. [1,2] This heterogeneity underpins modern risk-stratified management approaches, from active surveillance for low-risk disease to intensive combination therapy for metastatic disease.

Clinical Pearls

Adenocarcinoma Dominance: Over 95% of prostate cancers are adenocarcinomas arising from acinar glands in the peripheral zone (70%), with transition zone cancers (25%) typically more indolent. Rare variants include ductal, mucinous, and neuroendocrine carcinomas. [1]

Genomic Drivers: The TMPRSS2:ERG gene fusion occurs in approximately 50% of cases, placing the ERG oncogene under androgen receptor control. BRCA2 mutations confer the highest hereditary risk (8.6-fold increase) and predict aggressive disease, earlier onset, and superior response to PARP inhibitors. [3,4] HOXB13 G84E mutation increases risk 3-5 fold in men of European ancestry.

Metastatic Tropism: Prostate cancer exhibits marked osteotropism, with 80-85% of metastatic disease involving bone. Skeletal metastases are characteristically osteoblastic (sclerotic) affecting the axial skeleton (lumbar spine, pelvis, ribs), mediated by tumor-secreted endothelin-1 and Wnt proteins stimulating osteoblast activity. [2] Lytic lesions are rare and suggest aggressive variants or neuroendocrine differentiation.

PSA Kinetics: PSA velocity (rate of change) provides additional risk stratification beyond absolute value. A rise exceeding 0.75 ng/mL/year in men with PSA 4-10 ng/mL significantly increases cancer probability, even within "normal" ranges. [5] PSA doubling time (PSADT) following treatment predicts metastasis risk: PSADT under 3 months confers high risk, over 12 months suggests indolent disease.

Screening Controversies: The USPSTF (2018) recommends individualized decision-making for PSA screening in men 55-69 years after discussing benefits and harms. [5] Screening reduces prostate cancer mortality by 20-30% but increases overdiagnosis and overtreatment of indolent disease. The Number Needed to Screen to prevent one death is approximately 1000 men. [5]

Red Flags - Immediate Assessment Required:

• Lower urinary tract symptoms in men over 50 (urgency, frequency, nocturia, weak stream)
• Hematospermia (blood in semen) - warrants PSA and imaging
• Bone pain, particularly nocturnal back pain resistant to NSAIDs
• Neurological symptoms: leg weakness, sensory changes, sphincter dysfunction (spinal cord compression)
• Unexplained weight loss or constitutional symptoms
• Acute urinary retention in absence of benign prostatic hyperplasia history

Risk Factors:

Non-Modifiable Risk Factors:

• Age: Strongest risk factor. Incidence increases exponentially after age 50; median age at diagnosis 66 years. [1,2] Risk of clinically detected cancer: 1 in 350 for men under 50, rising to 1 in 7 for men aged 60-79.
• Race/Ethnicity: African-American men have 1.7-fold higher incidence and 2.2-fold higher mortality compared to Caucasian men. [6] Lowest rates in Asian populations. Disparities reflect genetic factors, socioeconomic determinants, and healthcare access.
• Family History: First-degree relative with prostate cancer increases risk 2-3 fold. Two or more affected relatives increase risk 5-11 fold. Earlier onset in relatives predicts higher risk. [2]
• Genetic Factors: BRCA1/2 mutations (8.6-fold for BRCA2), HOXB13 G84E, Lynch syndrome, ATM mutations. [3,4] Approximately 10-15% of metastatic castration-resistant prostate cancer harbors homologous recombination repair (HRR) defects.

Modifiable Risk Factors:

• Diet: High red/processed meat and saturated fat intake associated with increased risk. Prospective studies show 12-15% increased risk per 100g/day red meat consumption. [2]
• Obesity: BMI over 30 associated with 15-20% increased risk of aggressive/lethal disease, though paradoxically lower risk of low-grade disease. [2] Obesity predicts worse outcomes and treatment-related complications.
• Physical Activity: Regular exercise (3+ hours/week vigorous activity) reduces risk by 10-20% and improves outcomes. [2]
• Smoking: Current smoking associated with 20-30% increased risk and worse prognosis, including higher-grade tumors and increased mortality. [2]

Protective Factors:

• 5α-Reductase Inhibitors: Finasteride (5mg daily) reduces prostate cancer incidence by 24.8% (PCPT trial), though may increase high-grade disease detection. [2] Dutasteride shows similar 22.8% risk reduction (REDUCE trial).
• Dietary Factors: Mediterranean diet pattern, tomato products (lycopene), cruciferous vegetables, and omega-3 fatty acids show protective associations in observational studies. [2]
• Vitamin D: Adequate levels associated with lower risk, though supplementation trials have not confirmed benefit.
• Aspirin: Regular use shows modest protective association in some cohorts, mechanism unclear.

2. Epidemiology

Prostate cancer exhibits significant geographic and ethnic variation in incidence and mortality, reflecting differences in genetic susceptibility, screening practices, dietary patterns, and healthcare access. The global burden continues to rise due to aging populations and improved detection methods, though mortality has declined in high-income countries with widespread PSA screening and treatment advances. [1,2]

Global Burden:

• Incidence: Approximately 1.4 million new cases annually worldwide (2020 GLOBOCAN data), representing 14.1% of all male cancers and 7.3% of all cancers. [1]
• Prevalence: Cumulative prevalence exceeds 10 million men globally
• Age-standardized incidence: 29.3 per 100,000 men globally, ranging from 6.3 in South-Central Asia to 79.8 in Northern Europe. [1]
• Lifetime risk: 1 in 8 men (12.5%) will develop prostate cancer in high-income countries; 1 in 40 (2.5%) in low-income regions. [1]
• Age distribution: Peak incidence 65-74 years, median age at diagnosis 66 years. Rare before age 40 (less than 1% of cases).

Mortality Trends:

• Global mortality: Approximately 375,000 deaths annually, accounting for 6.8% of male cancer deaths worldwide. [1]
• Age-standardized mortality rate: 7.7 per 100,000 men globally, with highest rates in Caribbean (26.3) and Sub-Saharan Africa (19.9). [1]
• Temporal trends:
  • "High-income countries: 30-50% mortality decline since 1990s due to PSA screening and improved therapies. [2]"
  • "Low-middle income countries: Stable or rising mortality due to limited screening, late presentation, and treatment access barriers."
• 5-year relative survival: Over 98% in US/UK for localized disease; 30-35% for distant metastatic disease. [2]

Geographic Variation:

• Highest incidence: Northern/Western Europe, North America, Australia/New Zealand, Caribbean (ASR 60-110 per 100,000)
• Intermediate incidence: Southern/Eastern Europe, South America (ASR 30-60 per 100,000)
• Lowest incidence: South-Central Asia, Northern Africa (ASR under 15 per 100,000)
• Incidence-mortality paradox: High-incidence regions often have lower mortality rates (reflecting screening-detected indolent disease), while low-incidence regions have higher case-fatality rates (advanced-stage presentation).

Ethnic Disparities:

• African-American men: 1.7-fold higher incidence, 2.2-fold higher mortality, present at younger age with more aggressive disease. [6] Multifactorial etiology including genetic variants (8q24 risk locus), socioeconomic factors, and structural healthcare inequities.
• Asian men: Lowest incidence globally, though rates increasing with Westernization and dietary changes.
• Hispanic men: Intermediate incidence and mortality, underrepresented in clinical trials.

Age-Specific Rates (per 100,000 men):

• Age 40-44: 10 cases
• Age 50-54: 100 cases
• Age 60-64: 450 cases
• Age 70-74: 850 cases
• Age 80+: 1000 cases

Screening Impact:

• PSA screening introduction (1990s) caused incidence surge (50-70% increase) followed by plateau
• Stage migration: 75% now diagnosed with localized disease vs. 50% in pre-PSA era
• Overdiagnosis estimated at 20-50% of screen-detected cancers in some cohorts [5]

3. Pathophysiology

Prostate cancer develops through a multi-step process involving genetic and epigenetic alterations that disrupt normal prostate epithelial cell growth and differentiation.

Pathophysiology Steps

Step 1: Initiation and Genomic Alterations

• Genetic Driver: Somatic mutations accumulate in luminal epithelial cells. The most common is the TMPRSS2:ERG gene fusion (approx. 50% of cases), which puts the ERG oncogene under the control of an androgen-responsive promoter.
• Tumor Suppressors: Inactivation of PTEN, TP53, and RB1 loss accelerates progression.
• Inflammation: Proliferative Inflammatory Atrophy (PIA) caused by oxidants/infection may be a precursor lesion.

Step 2: Prostatic Intraepithelial Neoplasia (PIN)

• Precursor: High-Grade PIN (HGPIN) consists of benign glands with cytologic atypia (nucleomegaly, hyperchromasia).
• Architecture: The basal cell layer is preserved (key distinction from carcinoma), but the basement membrane is intact.
• Microenvironment: Stromal changes begin to support angiogenesis.

Step 3: Invasive Adenocarcinoma

• Invasion: Loss of the basal cell layer and disruption of the basement membrane allows invasion into the prostatic stroma.
• Dependency: The tumor is Androgen Dependent. Testosterone enters the cell, is converted to Dihydrotestosterone (DHT) by 5-alpha-reductase, and binds the Androgen Receptor (AR) to drive transcription of growth factors.
• Perineural Invasion: A common mechanism of extraprostatic spread, tracking along nerve sheaths.

Step 4: Local Progression & Metastasis

• Capsular Breach: Tumor extends into periprostatic fat, seminal vesicles (T3b), or adjacent organs (bladder neck/rectum - T4).
• Lymphatics: Spread to obturator and internal iliac nodes.
• Hematogenous: Spread to the axial skeleton via the Batson venous plexus.
• Osteoblastic Mets: Tumor cells secrete Endothelin-1 and Wnt proteins, stimulating osteoblasts to lay down new bone (sclerotic lesions).

Step 5: Castration Resistance (CRPC)

• Adaptation: Following Androgen Deprivation Therapy (ADT), tumor cells evolve mechanisms to survive low androgen levels.
• Mechanisms:
  1. AR Amplification: Making more receptors.
  2. Splice Variants: AR-V7 (constitutively active without ligand).
  3. Intratumoral Synthesis: Tumor makes its own testosterone.
  4. Neuroendocrine Transdifferentiation: Loss of AR dependence (aggressive).

4. Clinical Presentation

Prostate cancer often presents asymptomatically in early stages, detected through screening. Symptomatic presentation typically indicates locally advanced or metastatic disease.

Asymptomatic (Screening-Detected:

• No symptoms, detected by elevated PSA or abnormal DRE
• Represents majority of contemporary diagnoses

Lower Urinary Tract Symptoms (LUTS:

• Obstructive: Weak stream, hesitancy, incomplete emptying
• Irritative: Frequency, urgency, nocturia
• Often indistinguishable from benign prostatic hyperplasia

Locally Advanced Disease:

• Pelvic pain or discomfort
• Hematospermia
• Bladder outlet obstruction symptoms
• Lower extremity edema (venous/lymphatic obstruction Metastatic Disease:
• Bone pain (osteoblastic metastases to spine, pelvis, ribs- Pathologic fractures
• Spinal cord compression (back pain, weakness, sensory changes- Visceral metastases: Lymphadenopathy, hepatomegaly, pulmonary symptoms

Paraneoplastic Syndromes:

• Hypercalcemia
• Thrombosis
• Anemia of chronic disease

5. Clinical Examination

Digital Rectal Examination (DRE:

• Assesses prostate size, consistency, nodularity
• Abnormal findings: Hard nodules, asymmetry, induration
• Sensitivity: 50-70% for palpable tumors
• Specificity: 60-80%

General Physical Examination:

• Lymph node assessment: Supraclavicular, inguinal nodes
• Abdominal examination: Hepatomegaly, masses
• Neurological assessment: If spinal cord compression suspected
• Performance status evaluation

Specialized Assessments:

• Per rectal examination under anesthesia if indicated
• Bone tenderness assessment for metastatic evaluation
• Lower extremity edema assessment

Key Findings:

• Firm/hard prostate nodule suggests malignancy
• Asymmetrical prostate enlargement
• Loss of rectal tone may indicate advanced local disease
• CVA tenderness suggests bladder involvement

6. Investigations

A systematic, risk-stratified approach to investigation balances accurate diagnosis and staging against overdetection of clinically insignificant disease. Modern imaging (multiparametric MRI, PSMA PET) has transformed staging accuracy. [7,8]

Biochemical Markers

Prostate-Specific Antigen (PSA):

• Total PSA: Serum glycoprotein produced by prostate epithelium. Levels elevated in prostate cancer, BPH, prostatitis, recent DRE, ejaculation. [5]
• Normal ranges: Historically less than 4 ng/mL, but age-adjusted thresholds improve specificity:
  • 40-49 years: greater than 2.5 ng/mL
  • 50-59 years: greater than 3.5 ng/mL
  • 60-69 years: greater than 4.5 ng/mL
  • 70+ years: greater than 6.5 ng/mL
• Free PSA ratio: Free PSA/total PSA. Lower ratios (under 10-15%) suggest cancer; higher ratios (over 25%) favor BPH. Improves specificity in PSA 4-10 ng/mL range. [5]
• PSA density: PSA/prostate volume (calculated from TRUS or MRI). Greater than 0.15 ng/mL/cc suggests cancer. Useful in large glands.
• PSA velocity: Annual rate of change. Greater than 0.75 ng/mL/year raises suspicion. [5]
• Limitations: Organ-specific, not cancer-specific. Lacks sensitivity (15% of cancers occur with PSA under 4 ng/mL) and specificity (75% of elevated PSA from benign causes). [5]

Novel Biomarkers (Emerging):

• 4Kscore: Combines total PSA, free PSA, intact PSA, hK2 with clinical variables. Predicts high-grade cancer risk.
• Prostate Health Index (PHI): Combines total PSA, free PSA, [-2]proPSA. Improves detection of clinically significant cancer.
• PCA3 urine test: Prostate-specific mRNA marker. Limited sensitivity.
• ExoDx Prostate IntelliScore: Exosomal RNA assay from urine.

Other Biochemistry:

• Testosterone: Baseline essential before ADT initiation. Castrate level defined as under 50 ng/dL (under 1.7 nmol/L), though modern assays use under 20 ng/dL threshold.
• Alkaline phosphatase: Elevated in bone metastases (osteoblastic activity).
• LDH: Elevated in high-volume metastatic disease, prognostic marker.
• Hemoglobin: Anemia common in advanced disease.
• Renal function: Baseline and monitoring for bilateral ureteric obstruction.

Imaging Studies

Multiparametric MRI (mpMRI):

• Indication: Recommended before prostate biopsy in biopsy-naive men with clinical suspicion (EAU/AUA guidelines). [7,9]
• Sequences: T2-weighted, diffusion-weighted imaging (DWI), dynamic contrast enhancement (DCE).
• PI-RADS v2.1 Scoring (Prostate Imaging Reporting and Data System): [7]
  • "PI-RADS 1-2: Clinically significant cancer highly unlikely (less than 5% risk)"
  • "PI-RADS 3: Equivocal (10-15% risk)"
  • "PI-RADS 4: Likely clinically significant cancer (30-50% risk)"
  • "PI-RADS 5: Highly likely clinically significant cancer (over 50% risk)"
• Performance: Negative predictive value 76-94% for excluding Gleason Grade Group ≥2 disease. [7]
• Limitations: Reader-dependent, variable performance across centers, false positives from prostatitis/BPH.

PSMA PET/CT:

• Indication: Primary staging in high-risk disease, biochemical recurrence, metastatic disease assessment. [8,10]
• Tracers: 68Ga-PSMA-11, 18F-PSMA-1007, 18F-DCFPyL. Superior to conventional imaging.
• Performance: Detection rate 33% at PSA 0.2-0.5 ng/mL, 45% at 0.5-1.0 ng/mL, 57% at 1-2 ng/mL, over 95% at over 2 ng/mL for recurrence. [8,10]
• Advantages: Higher sensitivity/specificity than bone scan and CT for nodal and skeletal metastases. Alters management in 15-30% of cases. [8,10]
• Limitations: False positives (inflammation, other malignancies), availability, cost.

Bone Scintigraphy (Tc-99m MDP bone scan):

• Indication: Staging in high-risk disease (PSA over 20, Gleason ≥8, T3-4) or bone symptoms. [9]
• Performance: Sensitivity 80-90%, specificity 60-80%. Inferior to PSMA PET.
• Findings: Multiple focal areas of increased uptake in axial skeleton. Superscan pattern in extensive disease.
• Limitations: False positives (arthritis, trauma, Paget's), low sensitivity for lytic/marrow-only lesions.

CT Chest/Abdomen/Pelvis:

• Indication: Staging high-risk disease for nodal and visceral metastases.
• Performance: Low sensitivity (36-42%) for lymph node metastases (size-based criteria: short axis over 8-10 mm). PSMA PET superior.
• Findings: Lymphadenopathy (obturator, internal/external iliac, presacral), visceral metastases (liver, lung - rare).

Transrectal Ultrasound (TRUS):

• Role: Guidance for prostate biopsy, volume estimation. Poor diagnostic accuracy for cancer (hypoechoic lesions nonspecific).
• Doppler: Increased vascularity suggests malignancy (low specificity).

Biopsy and Histopathology

Biopsy Techniques:

• Systematic TRUS-guided biopsy: 10-12 core sampling (apex, mid-gland, base bilaterally). Standard approach.
• MRI-targeted biopsy: Targets PI-RADS 3-5 lesions. Higher detection of clinically significant cancer (Gleason Grade Group ≥2), fewer cores needed. [7]
• Combined approach: MRI-targeted plus systematic cores. Highest detection rate.
• Transperineal approach: Lower infection risk (under 1% vs. 1-3% for transrectal), equivalent cancer detection. Increasing adoption.
• Saturation biopsy: 20-40 cores. Reserved for persistent suspicion with prior negative biopsies.

Gleason Grading System and Grade Groups:

The Gleason score (sum of two most common architectural patterns, 1-5 scale) has been the gold standard since 1966, revised in 2005 and 2014. The ISUP Grade Group system (2014) simplifies prognostic stratification. [11]

Key Histologic Features:

• Perineural invasion (PNI): Present in 15-40% of biopsies. Indicates extraprostatic extension risk but not independent adverse prognostic factor.
• Lymphovascular invasion (LVI): Rare in biopsies, predicts lymph node metastases.
• Intraductal carcinoma: Aggressive feature, often associated with Gleason pattern 4-5.
• Cribriform pattern: Within Gleason pattern 4, predicts worse outcomes than fused glands.
• Percentage core involvement: Over 50% cancer in cores predicts adverse outcomes.
• Number of positive cores: More positive cores indicate higher disease volume.

Immunohistochemistry:

• AMACR (P504S): Positive in 80-90% of prostate cancers (cytoplasmic).
• p63 + HMWCK (34βE12): Highlights basal cells (absent in cancer).
• ERG: Positive in 50% (TMPRSS2:ERG fusion-associated).

Molecular Testing:

• Germline testing: Recommended for high-risk/metastatic disease (BRCA1/2, ATM, CHEK2, PALB2, Lynch syndrome genes). [3,4]
• Somatic testing: In metastatic castration-resistant disease for HRR defects (PARP inhibitor eligibility), microsatellite instability (MSI-H for pembrolizumab). [4]
• Genomic classifiers: Oncotype DX, Prolaris, Decipher. Predict metastasis risk, guide treatment decisions (utility debated).

Staging Investigations

TNM Staging System (AJCC 8th Edition):

T - Primary Tumor:

• TX: Cannot be assessed
• T0: No evidence of primary tumor
• T1: Clinically inapparent (not palpable/visible on imaging)
  • T1 a: Incidental, ≤5% of resected tissue (TURP)
  • T1 b: Incidental, greater than 5% of resected tissue
  • T1 c: Identified by needle biopsy (e.g., PSA elevation)
• T2: Palpable, confined to prostate
  • T2 a: ≤50% of one lobe
  • T2 b: greater than 50% of one lobe
  • T2 c: Both lobes
• T3: Extraprostatic extension
  • T3 a: Extraprostatic extension (unilateral/bilateral)
  • T3 b: Seminal vesicle invasion
• T4: Invasion of adjacent structures (bladder neck, rectum, levator ani, pelvic wall)

N - Regional Lymph Nodes:

• NX: Cannot be assessed
• N0: No regional lymph node metastasis
• N1: Regional lymph node metastasis

M - Distant Metastasis:

• M0: No distant metastasis
• M1: Distant metastasis
  • M1 a: Non-regional lymph nodes
  • M1 b: Bone
  • M1 c: Other sites (with or without bone)

Prognostic Stage Groups (incorporate T, N, M, Grade Group, PSA):

• Stage I: T1-2a, N0, M0, Grade Group 1, PSA under 10
• Stage II: T1-2c, N0, M0, Grade Group 1-2, PSA under 20
• Stage III: T3, N0, M0, any Grade/PSA OR any T, N0, M0, Grade Group 5, any PSA
• Stage IV: T4, N0, M0 OR any T, N1, M0 OR any T, any N, M1

Risk Stratification Systems

NCCN Risk Groups (widely used for treatment selection):

D'Amico Classification (historical, still referenced):

• Low: PSA ≤10 AND Gleason ≤6 AND T1c-T2a
• Intermediate: PSA 10-20 OR Gleason 7 OR T2b
• High: PSA greater than 20 OR Gleason 8-10 OR ≥T2c

CAPRA Score (Cancer of the Prostate Risk Assessment): 0-10 point scale incorporating age, PSA, Gleason, stage, percent positive cores. Predicts recurrence and mortality.

7. Management

Management is highly individualized based on risk stratification, patient age, life expectancy (less than 10 years vs. greater than 10 years), comorbidities, functional status, and informed patient preference after shared decision-making. The treatment landscape has evolved dramatically with landmark trials establishing active surveillance for low-risk disease and combination systemic therapy for advanced disease. [9,12,13,14]

Management Algorithm

COMPREHENSIVE PROSTATE CANCER MANAGEMENT PATHWAY
================================================

                    DIAGNOSIS CONFIRMED
                    (Biopsy Grade Group, PSA, cStage)
                            |
                            v
            +---------------+---------------+
            |                               |
    LOCALIZED/LOCALLY ADVANCED         METASTATIC (M1)
    (M0: No distant metastases)        (Bone, nodes, visceral)
            |                               |
            v                               v
    RISK STRATIFICATION             CASTRATE STATUS?
    (NCCN/D'Amico)                         |
            |                    +----------+----------+
            |                    |                     |
    +-------+-------+-------+    CASTRATE-NAÏVE    CASTRATE-RESISTANT
    |       |       |       |    (mHSPC)          (mCRPC, PSA rising
    |       |       |       |        |             despite ADT)
  VERY   INTER-   HIGH    V.HIGH     |                |
  LOW/   MEDIATE  RISK    RISK       v                v
  LOW                                |                |
    |       |       |       |        |                |
    v       v       v       v        v                v
                                     |                |
┌─────────────────────────────────────────────────────┐
│ LOCALIZED DISEASE MANAGEMENT (M0)                  │
└─────────────────────────────────────────────────────┘

VERY LOW RISK                  LOW RISK
(GG1, PSAless than 10, T1c,            (GG1, PSAless than 10, T1-2a)
 less than 3 cores, PSADless than 0.15)              |
        |                           |
        +----------+----------------+
                   |
            ACTIVE SURVEILLANCE (Preferred)
            • PSA q3-6 months
            • Confirmatory biopsy 6-18 months
            • Repeat biopsy q2-5 years
            • mpMRI q1-3 years
            • Triggers: Grade progression, high-volume
                       GG2, PSADTless than 3 years, patient preference
                   |
        +----------+----------+
        |                     |
    PSA STABLE          PROGRESSION
        |                     |
   CONTINUE              DEFINITIVE
   MONITORING            TREATMENT
                              |
                         (See below)

FAVORABLE INTERMEDIATE                 UNFAVORABLE INTERMEDIATE
(GG2, PSA 10-20, T2b-c,               (GG3, or multiple intermediate
 less than 50% cores positive)                  risk factors, or cribriform)
        |                                      |
        +--------------------------------------+
                        |
            +-----------+-----------+
            |           |           |
    ACTIVE      RADICAL       EBRT + ADT
    SURVEILLANCE PROSTATECTOMY (4-6 months)
    (select pts) ± PLND               OR
        |           |          BRACHY + EBRT
        |           |                 |
        |           |                 |
        +-----+-----+--------+--------+
              |              |
        CURATIVE      PSA FOLLOW-UP
        INTENT         q3-6 months
                            |
                      BCR? (PSA rise)
                            |
                +-----+-----+-----+
                |           |     |
           SALVAGE RT   SALVAGE  OBSERVATION
           (if post-RP) SURGERY  (slow PSADT)
                        (if post-RT)

HIGH RISK                             VERY HIGH RISK
(GG4-5, PSA> 20, T3a)                 (T3b-4, or primary GG5,
        |                             or > 4 cores GG4-5)
        |                                     |
        +-------------------------------------+
                        |
            +-----------+-----------+
            |                       |
    RADICAL PROSTATECTOMY     EBRT + LONG-TERM ADT
    + Extended PLND           (2-3 years) ± Docetaxel
    + Adjuvant/Salvage RT/ADT      |
            |                      |
            |              CONSIDER TRIPLET:
            |              • EBRT
            |              • ADT
            |              • Novel AR agent or docetaxel
            |                      |
    +-------+-------+--------------+
    |               |
PSA UNDETECTABLE  BIOCHEMICAL RECURRENCE
    |               |
SURVEILLANCE    RESTAGING (PSMA PET)
q3-6 months         |
                +---+---+
                |       |
            LOCAL  DISTANT METS
            RECUR    → mCRPC pathway
                |
            SALVAGE RT
            ± ADT


┌─────────────────────────────────────────────────────┐
│ METASTATIC HORMONE-SENSITIVE (mHSPC)               │
└─────────────────────────────────────────────────────┘

        NEW METASTATIC DIAGNOSIS (M1)
        Bone scan/PSMA PET confirms mets
                    |
            VOLUME ASSESSMENT
                    |
        +-----------+-----------+
        |                       |
   HIGH VOLUME              LOW VOLUME
   (Visceral mets OR        (less than 4 bone lesions,
   ≥4 bone with ≥1         no visceral, all in
   beyond spine/pelvis)     vertebrae/pelvis)
        |                       |
        |                       |
        v                       v
   
   ADT + DOUBLET THERAPY:      ADT + NOVEL AR AGENT
   • ADT + Docetaxel 75mg/m²   • ADT + Abiraterone 1000mg daily
     x6 cycles (CHAARTED)        + prednisone 5mg BID (LATITUDE)
        OR                          OR
   • ADT + Abiraterone         • ADT + Enzalutamide 160mg daily
     (LATITUDE, STAMPEDE)         (ENZAMET, ARCHES)
        OR                          OR
   • ADT + Enzalutamide        • ADT + Apalutamide 240mg daily
     (ENZAMET)                    (TITAN)
        OR                          OR
   • ADT + Apalutamide         • ADT + RT to primary prostate
     (TITAN)                      (STAMPEDE - low volume)
        OR
   • TRIPLET: ADT + Docetaxel
     + Darolutamide (ARASENS)
                |
        PSA MONITORING q3 months
        Testosterone: confirm castrate
        Imaging: q6-12 months initially
                |
        +-------+-------+
        |               |
   PSA STABLE      PSA RISING / NEW METS
   (RESPONDING)    (Testosterone less than 50 ng/dL)
        |               |
   CONTINUE            v
   SAME REGIMEN   METASTATIC CRPC (see below)


┌─────────────────────────────────────────────────────┐
│ METASTATIC CASTRATION-RESISTANT (mCRPC)            │
└─────────────────────────────────────────────────────┘

    CASTRATE TESTOSTERONE (less than 50 ng/dL)
    + PSA PROGRESSION or NEW LESIONS
                |
    +-----MANDATORY TESTING-----+
    |                           |
    • HRR mutation testing      • PSMA PET imaging
      (BRCA1/2, ATM, etc.)      • Assess disease sites
      via tumor/germline        • Symptom assessment
                |
                v
    +--------TREATMENT SEQUENCING--------+
    |           |           |            |
    |           |           |            |
FIRST-LINE  HRR MUT+    BONE-PREDOMINANT  HEAVILY
mCRPC      (BRCA/ATM)   SYMPTOMATIC      PRE-TREATED
    |           |            |               |
    v           v            v               v

ASYMPTOMATIC/        PARP INHIBITOR      RADIUM-223        Lu-177-PSMA
OLIGO-SYMPTOMATIC    • Olaparib 300mg    55 kBq/kg IV      7.4 GBq IV
                       BID (PROfound)      q4 weeks x6       q6 weeks x4-6
Options (sequence     • Rucaparib         (ALSYMPCA)        (VISION trial)
based on prior Rx,    • Niraparib         
fitness, preference):                     Indication:       Requirements:
                      Requirements:        • Bone mets       • PSMA+ on PET
• Abiraterone +       • BRCA1/2 or        • No visceral     • Prior taxane
  prednisone            ATM mutation       • Symptomatic     • Prior AR agent
  (COU-AA-302)        • Post AR agent                       
                                          Avoid with         Toxicity:
• Enzalutamide        Toxicity:           novel AR agent    • Dry mouth 40%
  (PREVAIL)           • Anemia 50%        (increased        • Cytopenias
                      • Nausea 40%        fractures)        • Fatigue
• Docetaxel           • Fatigue                             
  75 mg/m² q3wk                                             PSA response:
  (TAX 327)                                                 46%
                                                            Median OS: 15.3mo
                      Median rPFS:
PSA response:         7.4 mo (BRCA)
50-60%                
Median OS:
32-35 months

            |
    PROGRESSION ON FIRST-LINE
            |
            v

SECOND-LINE / SALVAGE OPTIONS

Post-AR Agent (Abi/Enza):     Post-Docetaxel:
• Switch to Docetaxel         • Cabazitaxel 20-25 mg/m²
  75 mg/m² q3wk                 q3wk (TROPIC trial)
  + G-CSF support               + G-CSF mandatory
  Median OS: 18-20 mo           Median OS: 15.1 mo
                                Dose: 20mg better
• Alternative AR agent          tolerated than 25mg
  (if no prior cross-use)
  PSA response: 20-30%        • Alternative AR agent
rPFS: 3-6 months              (if chemo-first strategy)

• Radium-223 (if bone-only)   • Radium-223 (if bone sx)

• Lu-177-PSMA (if eligible)   • Lu-177-PSMA (if PSMA+)

• Clinical trial              • PARP inhib (if HRR mut)

                              • Clinical trial

            |
    THIRD-LINE AND BEYOND
            |
    +-------+-------+-------+
    |       |       |       |
    
Best      Supportive  Clinical   Immuno-
Supportive Care for   Trial      therapy
Care      Symptoms    (novel     (if MSI-H/
          • Pain Rx    agents)    dMMR)
          • RT                    Pembro
          • Bone Rx              (rare)


┌─────────────────────────────────────────────────────┐
│ NON-METASTATIC CRPC (nmCRPC)                       │
│ Rising PSA despite castrate testosterone, M0      │
└─────────────────────────────────────────────────────┘

    PSA > 2 ng/mL, PSADT less than 10 months
    Castrate testosterone
    Imaging negative (M0)
            |
    SECOND-GENERATION AR INHIBITORS
            |
    +-------+-------+-------+
    |       |       |
    
Apalutamide  Enzalutamide  Darolutamide
240mg daily  160mg daily   600mg BID
(SPARTAN)    (PROSPER)     (ARAMIS)
    |           |             |
MFS: 40.5mo  MFS: 36.6mo   MFS: 40.4mo
vs 16.2mo    vs 14.7mo     vs 18.4mo

All improve MFS and delay metastasis
All continued with ongoing ADT

Treatment Continuum Overview

Localized Disease (T1-T2, N0, M0):

• Low risk: Active surveillance (preferred) or definitive therapy
• Favorable intermediate: Active surveillance or definitive therapy (surgery/radiation)
• Unfavorable intermediate/High risk: Definitive therapy +/- ADT +/- pelvic lymph node dissection

Locally Advanced (T3-4 and/or N1, M0):

• Multimodal therapy: External beam radiation + long-term ADT (2-3 years) +/- docetaxel
• OR radical prostatectomy + extended pelvic lymph node dissection + adjuvant/salvage therapy

Metastatic Hormone-Sensitive (M1, castrate-naive):

• ADT + docetaxel OR ADT + novel AR-targeted agent (abiraterone, enzalutamide, apalutamide) OR ADT + RT to primary OR triplet therapy (ongoing trials)

Metastatic Castration-Resistant (M1, castrate-resistant):

• Sequential systemic therapies: novel AR agents, chemotherapy (docetaxel, cabazitaxel), PARP inhibitors (HRR mutations), radium-223 (bone mets), Lu-177-PSMA-617

Active Surveillance

Rationale: Many low-risk prostate cancers are indolent; treatment causes significant morbidity (erectile dysfunction, incontinence); overtreatment common in PSA era. PROTECT trial showed no prostate cancer mortality difference at 15 years between monitoring, surgery, and radiotherapy for localized disease. [15]

Eligibility Criteria (NCCN/AUA):

• Very low risk: Grade Group 1, less than 3 cores positive, ≤50% any core, PSA density less than 0.15, cT1c
• Low risk: Grade Group 1, PSA less than 10, T1-T2a
• Favorable intermediate (select patients): Grade Group 2 (3+4), low volume, shared decision-making

Protocol:

• PSA: Every 3-6 months for 2 years, then every 6 months
• DRE: Annually (utility debated)
• Repeat biopsy: Within 6-18 months of diagnosis (confirmatory), then every 2-5 years or if PSA/DRE changes
• MRI: Baseline and serial imaging (intervals not standardized, typically every 1-3 years)

Triggers for Intervention:

• Grade reclassification to Grade Group ≥3
• High-volume Grade Group 2
• PSADT less than 3 years
• Patient anxiety/preference change

Outcomes: Long-term data (ProtecT, SPCG-4, PIVOT trials) show excellent cancer-specific survival (over 98% at 10-15 years for contemporary low-risk cohorts). [15,16] Approximately 30-50% of men on active surveillance ultimately receive definitive treatment within 10 years.

Radical Prostatectomy

Overview: Surgical removal of prostate, seminal vesicles, +/- pelvic lymph nodes. Gold standard for localized disease in men with greater than 10-year life expectancy.

Approaches:

• Robot-assisted laparoscopic (RALP): Most common (over 85% in US). Advantages: 3D visualization, precision, reduced blood loss (median 100-200 mL), shorter catheter time (7-10 days), faster recovery. Learning curve 20-40 cases. [17]
• Open retropubic: Historically standard. Equivalent oncologic outcomes to RALP in experienced hands.
• Laparoscopic (non-robotic): Less common, steep learning curve.
• Perineal: Rarely used, limited nodal access.

Surgical Technique - Key Steps:

1. Pelvic lymph node dissection (PLND): Extended PLND (obturator, internal iliac, external iliac, presacral nodes) for intermediate/high-risk. Removes median 15-20 nodes. Therapeutic and staging benefit debated.
2. Bladder neck division: Identify and preserve bladder neck (maintains continence).
3. Seminal vesicle dissection: En bloc removal with prostate.
4. Neurovascular bundle (NVB) preservation: Bilateral nerve-sparing for potency preservation in select patients (organ-confined disease, good baseline function). Interfascial (maximal preservation), intrafascial, or wide excision based on cancer risk.
5. Apical dissection: Critical for continence (preserve urethral length, avoid sphincter damage) and cancer control (positive margin risk).
6. Vesicourethral anastomosis: Bladder neck to urethra, watertight (5-7 interrupted sutures), catheter 5-14 days.

Oncologic Outcomes:

• Positive surgical margins (PSM): 10-30% overall (higher with pT3 disease). Apical and posterolateral most common. PSM increases biochemical recurrence risk (HR 2-3) but impact on metastasis/mortality less clear. [17]
• Biochemical recurrence (BCR): PSA ≥0.2 ng/mL on two occasions. Occurs in 20-40% by 10 years (risk-dependent). PSADT predicts progression: less than 3 months high risk, over 12 months indolent.
• Metastasis-free survival: 85-95% at 10 years for localized disease.
• Cancer-specific survival: Over 95% at 15 years for low/intermediate risk.

Functional Outcomes (at 12-24 months):

• Urinary continence: 0-pad continence 70-95% (definition-dependent). Stress incontinence most common. Predictors: age, prostate size, nerve sparing, surgeon volume. [17]
• Erectile dysfunction: 25-75% (baseline function, nerve sparing, age-dependent). Recovery continues 18-36 months. Penile rehabilitation (PDE5 inhibitors, vacuum devices, intracavernosal injections) may help.
• Anastomotic stricture: 2-10%, presents with obstructive symptoms, treated with dilation/incision.
• Lymphocele: 1-5% (with PLND), usually asymptomatic.

Complications:

• Perioperative: Bleeding (transfusion less than 5% for RALP), VTE (1-2%), rectal injury (less than 1%), ureteral injury (rare).
• Early: UTI, urinary retention, ileus.
• Late: Incontinence, erectile dysfunction, anastomotic stricture, bladder neck contracture (1-5%), inguinal hernia (5-20%).

Radiation Therapy

Modalities:

External Beam Radiation Therapy (EBRT):

• Technique: Intensity-modulated RT (IMRT) or volumetric-modulated arc therapy (VMAT) are standard. Delivers 74-81 Gy in 1.8-2 Gy fractions over 7-9 weeks (conventional) or 60-70 Gy in 2.5-3 Gy fractions over 4-5 weeks (moderate hypofractionation). [18]
• Ultra-hypofractionation/SBRT: 35-40 Gy in 5 fractions over 1-2 weeks. Non-inferior efficacy, fewer visits, similar toxicity in localized disease.
• Target volumes: Prostate +/- seminal vesicles +/- pelvic lymph nodes (high-risk).
• Outcomes: 10-year biochemical control: 75-85% low risk, 50-75% intermediate/high risk (with ADT). [18]

Brachytherapy:

• Low-dose-rate (LDR): Permanent radioactive seed implantation (I-125, Pd-103). Delivers 145 Gy (I-125) over months. Outpatient procedure under anesthesia. [18]

  • "Indications: Low/favorable intermediate risk, prostate less than 60 cc, good urinary function (IPSS less than 15), no prior TURP."
  • "Outcomes: Excellent biochemical control (85-95% at 10 years for low risk)."
  • "Complications: Urinary irritation/retention (10-20%, peaks 1-3 months), erectile dysfunction (30-50% by 5 years), rectal toxicity (less than 5%)."

• High-dose-rate (HDR): Temporary catheter-based delivery of Ir-192. Typically 1-2 fractions of 15-19 Gy (monotherapy) or boost (15 Gy single fraction + EBRT 45-50 Gy).

  • "Advantages: Dosimetry optimization, no permanent seeds, suitable for larger prostates."
  • "Outcomes: Equivalent or superior to LDR/EBRT alone for intermediate/high risk."

Combination Therapy: EBRT + brachytherapy boost for unfavorable intermediate/high-risk disease. Improves biochemical control but higher toxicity.

Androgen Deprivation Therapy (ADT) with Radiation:

• Intermediate risk: Short-term ADT (4-6 months, starting 2 months before radiation) improves biochemical control and overall survival. [18]
• High risk: Long-term ADT (2-3 years) significantly improves metastasis-free survival, cancer-specific survival, and overall survival (RTOG 92-02, EORTC 22961 trials). [18]
• Very high risk/locally advanced: Consider ADT + docetaxel + radiation (STAMPEDE trial arm). [12]

Radiation Toxicity:

• Acute (during/within 3 months): Urinary frequency/urgency (30-50%), diarrhea (10-30%), rectal urgency, fatigue.
• Late (months to years):
  • "Urinary: Hematuria, stricture (5-15%)"
  • "Rectal: Bleeding (5-15%), proctitis, fistula (rare, less than 1%)"
  • "Sexual: Erectile dysfunction (30-60%, gradual onset over 2-5 years)"
  • "Secondary malignancy: Absolute risk less than 1% at 10 years (rectal, bladder)"

Androgen Deprivation Therapy (ADT)

Mechanism: Androgen receptor signaling drives prostate cancer growth. ADT reduces circulating testosterone to castrate levels (less than 50 ng/dL, ideally less than 20 ng/dL).

Agents:

GnRH Agonists (Luteinizing hormone-releasing hormone agonists):

• Agents: Leuprolide, goserelin, triptorelin. Depot injections (1, 3, 6-month formulations).
• Mechanism: Initial testosterone surge (first 1-2 weeks, managed with anti-androgen flare protection), then downregulation of GnRH receptors, suppression of LH/FSH, testicular androgen synthesis blocked.
• Adverse effects: Hot flashes (60-80%), sexual dysfunction (90% libido loss, 60-90% erectile dysfunction), fatigue, mood changes.

GnRH Antagonists:

• Agents: Degarelix (monthly), relugolix (oral daily).
• Mechanism: Competitive GnRH receptor blockade, no testosterone flare, faster castration (less than 7 days).
• Advantages: Lower cardiovascular risk vs. agonists (HERO trial: 54% reduction in major adverse cardiac events with relugolix). [19] Preferred in men with significant cardiovascular disease or metastatic spinal cord compression risk.

Bilateral Orchiectomy:

• Surgical castration: Immediate, permanent, cost-effective (single procedure). Rarely chosen due to psychological impact and irreversibility. Equivalent efficacy to medical ADT.

Anti-Androgens (first-generation):

• Agents: Bicalutamide (50 mg daily), flutamide, nilutamide.
• Mechanism: Competitive AR blockade (peripheral).
• Monotherapy: Less effective than castration. Bicalutamide 150 mg monotherapy: preserves sexual function but inferior cancer control in M0 disease.
• Combined androgen blockade (CAB): GnRH agonist + anti-androgen. Marginal overall survival benefit (2-3% at 5 years), increased toxicity. Not routinely recommended.

ADT Adverse Effects (critical to counsel patients): [19]

ADT Monitoring:

• Testosterone: Confirm castrate level (less than 50 ng/dL) at 1 month, then annually
• PSA: Every 3-6 months
• Bone density (DEXA): Baseline, every 1-2 years
• Metabolic panel: Glucose, lipids, liver function
• Cardiovascular risk assessment

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Definition: Newly diagnosed or recurrent metastatic disease that has not been treated with continuous ADT (castrate-naive).

Volume Classification:

• High-volume: CHAARTED criteria: Visceral metastases OR ≥4 bone lesions with ≥1 beyond vertebral bodies/pelvis. [13]
• Low-volume: Neither high-volume criterion met.

Risk Classification:

• High-risk: LATITUDE criteria: ≥2 of (1) Gleason ≥8, (2) ≥3 bone lesions, (3) visceral metastases.
• Low-risk: Less than 2 high-risk factors.

Treatment - Paradigm Shift:

Standard of care is combination therapy (ADT doublet/triplet), NOT ADT monotherapy. Multiple phase III trials established superiority of treatment intensification. [12,13,14]

Option 1: ADT + Docetaxel

• Regimen: Docetaxel 75 mg/m² IV every 3 weeks x 6 cycles + continuous ADT.
• Evidence: CHAARTED trial - median OS 57.6 months vs. 44.0 months with ADT alone (HR 0.61, p less than 0.001). Benefit greatest in high-volume disease (17-month OS improvement). [13]
• STAMPEDE docetaxel arm: OS HR 0.78, absolute benefit 10 months. [12]
• Toxicity: Neutropenia (12% febrile neutropenia), fatigue, neuropathy, alopecia, nausea. Requires good performance status (ECOG 0-1).

Option 2: ADT + Abiraterone

• Regimen: Abiraterone 1000 mg PO daily + prednisone 5 mg PO BID + continuous ADT.
• Mechanism: Abiraterone inhibits CYP17A1, blocking androgen synthesis in testes, adrenals, and tumor.
• Evidence:
  • "LATITUDE trial (high-risk): Median OS 53.3 vs. 36.5 months (HR 0.66, p less than 0.001), 3-year OS 66% vs. 49%. [14]"
  • "STAMPEDE abiraterone arm: OS HR 0.63 (metastatic), HR 0.75 (non-metastatic high-risk). [12]"
• Toxicity: Hypertension (20%), hypokalemia (10%), hepatotoxicity (5%), fluid retention. Requires prednisone (mineralocorticoid effects). Monitor BP, K+, LFTs.

Option 3: ADT + Enzalutamide

• Regimen: Enzalutamide 160 mg PO daily + continuous ADT.
• Mechanism: AR antagonist (competitive binding), blocks AR nuclear translocation, impairs DNA binding.
• Evidence:
  • "ARCHES trial: Metastasis-free survival HR 0.39."
  • "ENZAMET trial: 3-year OS 80% vs. 72% with ADT alone (HR 0.67). [20]"
• Toxicity: Fatigue (30%), hypertension (15%), hot flashes, diarrhea. Seizure risk (0.5%), avoid in predisposed patients.

Option 4: ADT + Apalutamide

• Regimen: Apalutamide 240 mg PO daily + continuous ADT.
• Mechanism: Next-generation AR antagonist (similar to enzalutamide).
• Evidence: TITAN trial - radiographic PFS HR 0.48, OS HR 0.67 (final analysis). [21]
• Toxicity: Similar to enzalutamide, plus rash (25%), hypothyroidism (8%).

Option 5: ADT + Darolutamide (emerging data)

• Regimen: Darolutamide 600 mg PO BID + ADT + docetaxel (ARASENS trial).
• Evidence: ARASENS trial (triplet therapy) - OS HR 0.68 vs. ADT + docetaxel. [22]
• Unique feature: Does not cross blood-brain barrier (no seizure risk), lower fatigue.

Option 6: Radiation to Primary (Prostate)

• STAMPEDE RT arm: Local RT to prostate in low-volume mHSPC improved OS (HR 0.68) and failure-free survival. [12] Emerging option, patient selection critical.

Treatment Selection:

• High-volume disease: ADT + docetaxel OR ADT + novel AR agent. Consider triplet (ADT + docetaxel + AR agent) in fit patients (ARASENS, PEACE-1 trials).
• Low-volume disease: ADT + novel AR agent OR ADT + RT to primary.
• Frail/elderly: ADT + novel AR agent (better tolerated than chemotherapy).

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Definition: Progression on continuous ADT with castrate testosterone (less than 50 ng/dL). Criteria: [23]

• Biochemical: PSA rise (≥2 ng/mL, 3 consecutive rises 1 week apart, 50% increase over nadir)
• Radiographic: New bone lesions (≥2 on bone scan) or soft tissue progression (RECIST)
• Symptomatic: Clinical progression

Mechanisms of Resistance: AR amplification, AR splice variants (AR-V7 constitutively active), intratumoral androgen synthesis, AR point mutations, lineage plasticity (neuroendocrine differentiation). [23]

Treatment Sequencing - Major Challenge:

No consensus on optimal sequence. Cross-resistance exists between AR-targeted agents (prior abiraterone predicts enzalutamide resistance, and vice versa). Chemotherapy and radionuclides have different mechanisms. [23,24]

First-Line mCRPC (Chemotherapy-Naive):

Option A: Abiraterone + Prednisone

• Evidence: COU-AA-302 trial - median OS 34.7 vs. 30.3 months (HR 0.81). rPFS 16.5 vs. 8.3 months. [23]
• Use: Asymptomatic/mildly symptomatic patients.

Option B: Enzalutamide

• Evidence: PREVAIL trial - median OS 32.4 vs. 30.2 months (HR 0.71). rPFS 20.0 vs. 5.4 months. [23]
• Use: Asymptomatic/mildly symptomatic patients. Equivalent efficacy to abiraterone (no head-to-head trial).

Option C: Docetaxel

• Regimen: 75 mg/m² IV every 3 weeks + prednisone 5 mg BID.
• Evidence: TAX327 trial (landmark 2004) - median OS 19.2 vs. 16.3 months with mitoxantrone (HR 0.76). First therapy to improve OS in mCRPC. [23]
• Use: Symptomatic patients, visceral metastases, rapid progression. Often deferred if used in mHSPC setting.

Option D: Radium-223 (bone metastases, no visceral disease)

• Regimen: 55 kBq/kg IV every 4 weeks x 6 doses.
• Mechanism: Alpha-emitter, homes to osteoblastic bone mets, short tissue penetration (2-10 cell diameters).
• Evidence: ALSYMPCA trial - median OS 14.9 vs. 11.3 months (HR 0.70). Delayed skeletal-related events, improved pain. [23]
• Indication: Symptomatic bone metastases, no visceral mets, not for lymph node only.
• Toxicity: Myelosuppression (thrombocytopenia 10-15%, neutropenia 5%), diarrhea.

Second-Line and Beyond:

Post-AR-Targeted Agent:

• Cabazitaxel: Taxane chemotherapy. TROPIC trial - median OS 15.1 vs. 12.7 months post-docetaxel (HR 0.70). [23] Dose 20-25 mg/m² q3weeks (20 mg less toxic, similar efficacy to 25 mg).
  • "Toxicity: Neutropenia (50% febrile neutropenia at 25 mg), diarrhea, neuropathy. G-CSF prophylaxis mandatory."
• Alternative AR agent: Modest benefit if no prior cross-exposure (abiraterone after enzalutamide: PSA response 20-30%, rPFS 3-6 months). [24]

PARP Inhibitors (HRR gene mutations):

• Indication: Tumors with BRCA1/2, ATM, or other HRR mutations (tested via tumor or germline). [4]
• Agents:
  • "Olaparib: PROfound trial - rPFS 7.4 vs. 3.6 months for BRCA1/2/ATM (HR 0.34), OS benefit in BRCA cohort. FDA-approved for BRCA1/2 or ATM-mutated mCRPC after enzalutamide/abiraterone. [4]"
  • "Rucaparib: TRITON2/3 trials - similar efficacy."
• Toxicity: Anemia, nausea, fatigue, thrombocytopenia.

Pembrolizumab (MSI-H/dMMR or TMB-High):

• Indication: Rare (less than 5% of prostate cancer). Microsatellite instability-high or mismatch repair deficient tumors.
• Evidence: KEYNOTE-199 - ORR 5% overall, 50% in MSI-H subset (small numbers).

Lu-177-PSMA-617 Radioligand Therapy:

• Indication: PSMA-positive mCRPC (PET scan) after prior taxane and AR agent.
• Evidence: VISION trial - median OS 15.3 vs. 11.3 months (HR 0.62), rPFS 8.7 vs. 3.4 months. [25]
• Regimen: 7.4 GBq IV every 6 weeks x 4-6 doses.
• Mechanism: Beta-emitter conjugated to PSMA-targeting ligand, internalized by PSMA+ tumor cells.
• Toxicity: Dry mouth (40%, salivary gland uptake), myelosuppression, fatigue, nausea.
• Availability: FDA-approved 2022, increasing access.

Sipuleucel-T (Provenge):

• Mechanism: Autologous cellular immunotherapy (patient APCs pulsed with PAP antigen).
• Evidence: IMPACT trial - median OS 25.8 vs. 21.7 months (HR 0.78). No PSA or radiographic response.
• Use: Asymptomatic/minimally symptomatic mCRPC. Expensive, logistically complex, rarely used given newer options.

Treatment Sequencing Considerations: [24]

1. HRR mutation testing mandatory upfront - if positive, prioritize PARP inhibitor.
2. Symptomatic bone disease - consider radium-223 early.
3. Visceral metastases/rapid progression - chemotherapy (docetaxel or cabazitaxel).
4. PSMA-positive, post-taxane/AR agent - Lu-177-PSMA eligible.
5. Avoid sequential AR agents if possible (poor cross-efficacy).
6. Trial enrollment strongly encouraged.

Supportive Care and Bone Health

Bone-Targeted Therapy (metastatic disease):

• Denosumab 120 mg SC monthly OR Zoledronic acid 4 mg IV monthly: Prevent skeletal-related events (pathologic fracture, cord compression, radiation/surgery to bone, hypercalcemia). Both equivalent efficacy. [9]
• Start: At mCRPC diagnosis with bone mets, or earlier if high skeletal disease burden.
• Toxicity: Osteonecrosis of jaw (1-2%, avoid invasive dental procedures), hypocalcemia (supplement calcium/vitamin D), renal impairment (zoledronic acid).

ADT-Related Bone Loss:

• Prevention: Calcium 1200 mg + Vitamin D 800-1000 IU daily.
• Treatment (if osteoporosis T-score ≤-2.5 or fragility fracture): Denosumab 60 mg SC every 6 months OR oral bisphosphonates (alendronate, risedronate).

Pain Management:

• Nociceptive bone pain: Opioids, NSAIDs, radiation (single 8 Gy fraction effective).
• Neuropathic pain: Gabapentin, pregabalin, duloxetine.
• Spinal cord compression (emergency): High-dose dexamethasone 16 mg daily, urgent MRI, neurosurgical/radiation oncology consultation. Decompressive surgery + RT or RT alone based on neurological status and prognosis.

Fatigue: Treat anemia (ESA if Hb less than 10 g/dL, consider transfusion), encourage exercise, address depression.

Genitourinary Symptoms:

• Hematuria: Tranexamic acid, catheterization + irrigation if clot retention.
• Bladder outlet obstruction: TURP or catheter (suprapubic if long-term).

8. Complications

Treatment-Related Complications (detailed in Management section above):

Surgical (Radical Prostatectomy):

• Urinary incontinence (5-20% persistent at 1 year), erectile dysfunction (30-75%), anastomotic stricture (2-10%), lymphocele (1-5% with PLND), bladder neck contracture (1-5%)
• Perioperative: bleeding (transfusion less than 5%), VTE (1-2%), rectal injury (less than 1%)

Radiation:

• Acute: urinary frequency/urgency (30-50%), diarrhea (10-30%), fatigue
• Late: rectal bleeding (5-15%), urethral stricture (5-15%), erectile dysfunction (30-60% at 5 years), secondary malignancy (less than 1% at 10 years)

ADT:

• Hot flashes (60-80%), sexual dysfunction (90%), osteoporosis (fracture risk 20-30% at 5 years), metabolic syndrome (50-60%), cardiovascular events (HR 1.2-1.5), cognitive changes (20-40%), gynecomastia (10-40%), anemia (80-90%)

Chemotherapy:

• Docetaxel: neutropenia (12% febrile), neuropathy, fatigue, alopecia
• Cabazitaxel: neutropenia (50% febrile at 25 mg/m²), diarrhea, neuropathy

Disease-Related Complications:

• Bladder outlet obstruction → retention, hydronephrosis
• Ureteric obstruction → obstructive nephropathy, renal failure
• Spinal cord compression → paraplegia (emergency)
• Pathologic fractures → pain, immobility
• Hypercalcemia → rare (osteoblastic metastases), but can occur with lytic lesions
• Bone marrow infiltration → cytopenias

9. Prognosis

Prognosis varies dramatically by risk category, with modern therapies substantially improving outcomes even in metastatic disease. [1,2]

5-Year Survival Rates (SEER data):

• Localized disease: 98-100%
• Regional disease (lymph node involvement): 95-100%
• Distant metastases: 30-35% (improved from 20-25% pre-2000s with novel agents)
• Overall 5-year relative survival: 97%

10-Year Survival by Risk Group Post-Radical Prostatectomy:

• Very low/Low risk: 95-98%
• Favorable intermediate: 90-95%
• Unfavorable intermediate: 80-90%
• High risk: 70-80%
• Very high risk: 50-70%

Biochemical Recurrence (BCR) Risk Post-Definitive Therapy:

• Low risk: 10-20% at 10 years
• Intermediate risk: 20-40% at 10 years
• High risk: 40-60% at 10 years

BCR to Metastasis Progression:

• PSADT greater than 12 months: Low risk of metastasis (less than 20% at 10 years)
• PSADT 3-12 months: Intermediate risk
• PSADT less than 3 months: High risk (greater than 50% at 10 years)

Metastatic Disease Survival with Modern Therapies:

• Metastatic hormone-sensitive: Median OS 5-6 years with combination therapy (vs. 3-4 years with ADT alone historically). [12,13,14]
• Metastatic castration-resistant: Median OS 2-4 years depending on volume, prior therapies, and HRR mutation status. [23,24,25]
• Post-Lu-177-PSMA: Median OS 15-19 months in heavily pretreated patients. [25]

Adverse Prognostic Factors:

• At diagnosis: High Gleason/Grade Group, high PSA, advanced stage, high-volume metastases, visceral metastases
• Post-treatment: Short PSADT (less than 3 months), short time to BCR (less than 2 years post-RP), Gleason score ≥8, persistent PSA post-surgery
• Metastatic CRPC: Visceral metastases, high LDH, high ALP, low hemoglobin, ECOG ≥2, presence of AR-V7 splice variant, absence of HRR mutations

Favorable Prognostic Factors:

• BRCA2/HRR mutations (predict PARP inhibitor response in mCRPC)
• Low-volume metastatic disease
• Long PSADT
• Good performance status
• Amenable to multimodal local therapy

Quality of Life Considerations:

• Treatment choice profoundly impacts functional outcomes (urinary, sexual, bowel)
• Active surveillance preserves QoL short-term but may cause anxiety
• Radical prostatectomy: immediate impact, potential recovery over 12-24 months
• Radiation: delayed effects, gradual decline in function over years
• ADT: progressive effects on bone, metabolic, cognitive, sexual domains
• Supportive care, rehabilitation, mental health support critical across disease trajectory

10. Follow-Up and Surveillance

Post-Radical Prostatectomy:

• PSA: 3, 6, 12 months, then every 6 months for 5 years, then annually
• BCR definition: PSA ≥0.2 ng/mL on two consecutive occasions
• Imaging: Not routine if PSA undetectable. If BCR, consider PSMA PET (especially if PSA greater than 0.2 ng/mL)
• Salvage RT: Most effective if PSA less than 0.5 ng/mL, ideally less than 0.2 ng/mL

Post-Radiation Therapy:

• PSA: 3, 6, 12 months, then every 6 months for 5 years, then annually
• BCR definition: PSA rise ≥2 ng/mL above nadir (Phoenix criteria)
• Nadir PSA: Typically reaches lowest level 18-24 months post-RT
• Salvage prostatectomy: Technically challenging, high complication rate, reserved for select patients

Active Surveillance:

• PSA: Every 3-6 months indefinitely
• DRE: Annually (some protocols)
• MRI: Every 1-3 years (emerging practice)
• Biopsy: Confirmatory within 6-18 months, then every 2-5 years or if progression triggers

Metastatic Disease on ADT:

• PSA: Every 3 months
• Testosterone: Confirm castrate level (less than 50 ng/dL), annually
• Imaging: Not routine if PSA stable and asymptomatic. Repeat if PSA progression or new symptoms.
• Bone health: DEXA every 1-2 years
• Metabolic monitoring: Glucose, lipids, LFTs every 6-12 months

mCRPC:

• PSA: Every cycle of chemotherapy, or every 6-12 weeks on oral therapies
• Imaging: Every 2-3 months initially, then every 3-6 months if stable
• Labs: CBC (myelosuppression risk), LFTs (abiraterone, oral agents), renal function

11. Patient Explanation

"What is Prostate Cancer?" Prostate cancer develops when cells in the prostate gland—a walnut-sized organ that produces fluid for semen—begin to grow abnormally. Most prostate cancers grow slowly and may never cause problems during your lifetime, which is why some men choose monitoring rather than immediate treatment. However, some prostate cancers can grow aggressively and spread to other parts of the body, particularly bones.

"How Did I Get This?" The exact cause is unknown, but several factors increase risk: age (most common over 65), family history (2-3 times higher risk if your father or brother had it), genetics (BRCA2 mutations increase risk 8-fold), and ethnicity (African-American men have highest risk). Diet high in red meat and obesity also contribute. It's NOT caused by sexual activity, masturbation, or having BPH (enlarged prostate).

"What Tests Will I Need?" Initial tests include:

• PSA blood test: Measures prostate-specific antigen. Elevated levels may suggest cancer but can also be raised by infection or benign enlargement.
• MRI scan: Shows suspicious areas in the prostate (PI-RADS score 1-5).
• Biopsy: Taking small tissue samples (10-12 cores) to diagnose cancer and determine grade (Gleason score/Grade Group 1-5).

If cancer is confirmed, staging tests may include bone scans or specialized PET scans to check if cancer has spread.

"What Are My Treatment Options?" Treatment depends on cancer aggressiveness, your age, overall health, and preferences:

• Active surveillance: Regular monitoring with PSA tests and repeat biopsies for low-risk cancer. Avoids treatment side effects while cancer remains indolent. About 30-50% of men eventually receive treatment, but many never need it.

• Surgery (radical prostatectomy): Complete removal of prostate, typically with robotic assistance. Offers excellent cure rates (over 90% at 10 years for localized disease). Hospital stay 1-2 days, catheter 5-14 days. Main risks: urinary leakage (5-20% long-term) and erectile dysfunction (30-75%).

• Radiation therapy: External beam (daily treatments for 4-9 weeks) or seed implants (brachytherapy, single procedure). Equivalent cure rates to surgery. Side effects: bowel urgency (5-15% long-term bleeding risk), urinary symptoms, erectile dysfunction (develops gradually over 2-5 years).

• Hormone therapy: Injections or pills that block testosterone (which fuels prostate cancer). Used with radiation for intermediate/high-risk disease, or alone for metastatic disease. Causes hot flashes, sexual changes, fatigue, bone thinning, weight gain.

• Chemotherapy: For advanced/metastatic disease not responding to hormones. Improves survival when combined with hormone therapy.

• Newer therapies: Targeted therapies (abiraterone, enzalutamide), PARP inhibitors (for certain gene mutations), radioactive treatments (Lu-177-PSMA) for advanced disease.

"What Are the Side Effects?" All treatments can affect urination, erections, and bowel function to varying degrees:

• Surgery: Immediate incontinence (usually improves to 80-95% control), erectile dysfunction (30-75%, may improve over 18-36 months with medications/injections/devices)
• Radiation: Gradual side effects, bowel urgency/bleeding (5-15%), urinary irritation, delayed erectile dysfunction
• Hormone therapy: Hot flashes (60-80%), complete loss of erections and libido while on treatment, bone thinning, weight gain, mood changes, increased heart disease risk
• Chemotherapy: Nausea, fatigue, hair thinning, numbness in hands/feet, low blood counts

"What Is My Prognosis?" Excellent for most men, especially if caught early:

• Localized disease: Over 98% alive at 5 years
• Spread to lymph nodes: 95-100% alive at 5 years
• Spread to bones/organs: 30-35% alive at 5 years, though improving with new treatments

Your specific prognosis depends on cancer grade (Gleason score), PSA level, and stage. Your doctor will classify you into risk categories (low, intermediate, high) to guide treatment and predict outcomes.

"What About My Sex Life?" All prostate cancer treatments affect sexual function to some degree:

• Erections may be weaker or absent immediately after surgery (75% report dysfunction), improving over 18-36 months with nerve-sparing surgery. Medications (Viagra, Cialis), injections, vacuum pumps, or penile implants can help.
• Radiation causes gradual decline, with 30-60% reporting dysfunction by 5 years.
• Hormone therapy causes complete loss of libido and erections while on treatment (usually reversible if hormone therapy is stopped).
• Ability to orgasm usually preserved, but ejaculate volume is reduced or absent (dry orgasm).

Discuss concerns openly with your doctor. Sexual rehabilitation programs and counseling are available.

"Will I Need Follow-Up?" Yes, lifelong monitoring:

• PSA blood tests: Every 3-6 months initially, then less frequently if stable
• Repeat biopsies (if on active surveillance): Every 2-5 years
• Imaging: Only if PSA rises or new symptoms develop
• Bone density scans: If on hormone therapy
• General health: Monitor heart health, diabetes risk, bone health (especially on hormone therapy)

Early detection of recurrence allows for salvage treatments (radiation after surgery, or additional therapies).

"Can I Prevent Recurrence?" While no guaranteed prevention, healthy lifestyle helps:

• Exercise regularly: 150+ minutes/week moderate activity reduces progression risk
• Maintain healthy weight: Obesity associated with aggressive disease
• Balanced diet: Mediterranean-style diet with vegetables, fish, limited red meat
• Don't smoke: Increases risk of aggressive disease and treatment failure
• Attend follow-ups: Catching recurrence early improves treatment success
• Manage treatment side effects proactively: Bone health (calcium, vitamin D, bone medications), cardiovascular health (control blood pressure, cholesterol), pelvic floor exercises (for incontinence)

12. References

1. Raychaudhuri S, Lin A, Montgomery RB. Prostate Cancer: A Review. JAMA. 2025;333(3):257-271. doi:10.1001/jama.2025.0228 PMID: 40063046

2. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The Epidemiology of Prostate Cancer. Cold Spring Harb Perspect Med. 2018;8(12):a030361. doi:10.1101/cshperspect.a030361 PMID: 30054404

3. Risdon EN, Chau CH, Price DK, Sartor O, Figg WD. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA. Oncologist. 2021;26(1):e115-e129. doi:10.1634/theoncologist.2020-0697 PMID: 32790034

4. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(22):2091-2102. doi:10.1056/NEJMoa1911440 PMID: 32343890

5. Fenton JJ, Weyrich MS, Durbin S, et al. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018;319(18):1914-1931. doi:10.1001/jama.2018.3712 PMID: 29801018

6. Smith ZL, Eggener SE, Murphy AB. African-American Prostate Cancer Disparities. Curr Urol Rep. 2017;18(10):81. doi:10.1007/s11934-017-0724-5 PMID: 28808871

7. Jochumsen MR, Bouchelouche K. PSMA PET/CT for Primary Staging of Prostate Cancer - An Updated Overview. Semin Nucl Med. 2024;54(1):39-45. doi:10.1053/j.semnuclmed.2023.07.001 PMID: 37487824

8. Eiber M, Herrmann K, Calais J, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med. 2018;59(3):469-478. doi:10.2967/jnumed.117.198119 PMID: 29123012

9. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2023 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2023;84(4):371-398. doi:10.1016/j.eururo.2023.04.016 PMID: 37201943

10. Seifert R, Emmett L, Rowe SP, et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol. 2023;83(5):405-412. doi:10.1016/j.eururo.2023.02.002 PMID: 36935345

11. Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol. 2016;69(3):428-435. doi:10.1016/j.eururo.2015.06.046 PMID: 26166626

12. Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447-460. doi:10.1016/S0140-6736(21)02437-5 PMID: 34953525

13. Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018;36(11):1080-1087. doi:10.1200/JCO.2017.75.3657 PMID: 29384722

14. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377(4):352-360. doi:10.1056/NEJMoa1704174 PMID: 28578639

15. Newcomb LF, Schenk JM, Zheng Y, et al. Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer. JAMA. 2024;331(21):1868-1878. doi:10.1001/jama.2024.6695 PMID: 38814624

16. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016;375(15):1415-1424. doi:10.1056/NEJMoa1606220 PMID: 27626136

17. Nahas WN, Rodrigues A, Rodrigues Gonçalves FE, et al. Perioperative, Oncological, and Functional Outcomes Between Robot-Assisted Laparoscopic Prostatectomy and Open Radical Prostatectomy: A Single-Center Experience. J Urol. 2024;211(6):860-868. doi:10.1097/JU.0000000000003967 PMID: 38723593

18. Pommier P, Ferré M, Blanchard P, et al. Prostate cancer brachytherapy: SFRO guidelines 2021. Cancer Radiother. 2022;26(1-2):190-199. doi:10.1016/j.canrad.2021.11.007 PMID: 34955422

19. Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825-836. doi:10.1016/j.eururo.2014.07.010 PMID: 25097095

20. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019;381(2):121-131. doi:10.1056/NEJMoa1903835 PMID: 31157964

21. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019;381(1):13-24. doi:10.1056/NEJMoa1903307 PMID: 31157964

22. Smith MR, Hussain M, Saad F, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386(12):1132-1142. doi:10.1056/NEJMoa2119115 PMID: 35179323

23. Cai C, Song L, Li F, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat. 2023;68:100962. doi:10.1016/j.drup.2023.100962 PMID: 37068396

24. Francini E, Agarwal N, Castro E, et al. Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review. Eur Urol. 2025;87(1):33-46. doi:10.1016/j.eururo.2024.09.008 PMID: 39306478

25. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322 PMID: 34161051

26. Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2021;79(2):263-282. doi:10.1016/j.eururo.2020.09.046 PMID: 33039206

27. Cattrini C, Caffo O, De Giorgi U, et al. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Systematic Review and Network Meta-Analysis. Cancers (Basel). 2022;14(7):1792. doi:10.3390/cancers14071792 PMID: 35406564

13. Examination Focus

Key Examination Findings

Digital Rectal Examination (DRE):

• Technique: Patient in left lateral position, knees flexed. Gentle insertion, palpate anterior rectal wall where prostate located.
• Normal prostate: Smooth, symmetrical, walnut-sized, consistency of thenar eminence, median sulcus palpable.
• Suspicious findings:
  • Hard, irregular nodule (high specificity 80-90%, low sensitivity 50-60%)
  • Asymmetrical enlargement
  • Fixed to surrounding structures (T4 disease)
  • Obliterated median sulcus
• Limitations: Cannot assess anterior/transition zone (25% of cancers), misses T1c disease, inter-observer variability.

Systemic Examination in Metastatic Disease:

• Lymph nodes: Supraclavicular (Virchow's node - distant metastasis), inguinal (pelvic nodal involvement)
• Abdominal: Hepatomegaly (liver metastases, rare), bladder distension (retention), renal angle tenderness (ureteric obstruction)
• Musculoskeletal: Spinal tenderness (vertebral metastases), reduced range of motion, pathologic fracture deformity
• Neurological: Lower limb weakness, sensory level, saddle anesthesia, anal tone (spinal cord compression - EMERGENCY)
• Lower extremities: Bilateral pedal edema (lymphatic/venous obstruction from pelvic adenopathy)
• Performance status: ECOG 0-4 assessment (guides treatment eligibility)

Clinical Scenarios for Examination

Scenario 1: Elderly Male with LUTS

• Presentation: 68-year-old man, nocturia x3, weak stream, hesitancy
• Differential: BPH vs. prostate cancer vs. bladder pathology vs. neurogenic bladder
• Approach:
  • DRE (benign smooth enlargement favors BPH, hard nodule suggests cancer)
  • PSA (interpret with age-adjustment, free PSA ratio if 4-10 ng/mL)
  • IPSS score (quantify symptom severity)
  • Post-void residual (bladder scanner)
  • Consider mpMRI if PSA elevated and suspicion high
• Key point: LUTS are NOT specific for cancer - most commonly BPH. However, LUTS + elevated PSA + abnormal DRE warrants investigation.

Scenario 2: Incidental PSA Elevation

• Presentation: 62-year-old asymptomatic man, routine PSA 6.8 ng/mL
• Approach:
  • Repeat PSA (exclude transient elevation from infection, recent ejaculation, vigorous exercise, DRE)
  • Calculate PSA density (obtain prostate volume via TRUS/MRI)
  • Free PSA ratio (if total PSA 4-10 ng/mL)
  • Risk calculator (PCPT, ERSPC) to estimate high-grade cancer probability
  • mpMRI (PI-RADS score guides biopsy decision)
  • "Shared decision-making: discuss biopsy risks/benefits, overdiagnosis concern"
• Key point: PSA 4-10 ng/mL is "gray zone"
• only 20-30% harbor cancer. Avoid reflex biopsy; use ancillary tests.

Scenario 3: Bone Pain in Known Prostate Cancer Patient

• Presentation: 74-year-old with mCRPC on abiraterone, new severe lower back pain
• Red flags: Night pain, progressive neurological symptoms, sphincter dysfunction
• Urgent assessment:
  • Neurological exam (motor, sensory, reflexes, anal tone)
  • "If any deficits: EMERGENCY - high-dose dexamethasone 16 mg IV, urgent MRI whole spine (within 24 hours), neurosurgery/radiation oncology consult"
  • "If no deficits: Plain X-rays (pathologic fracture?), bone scan or PSMA PET, PSA, ALP"
• Management: Analgesia (opioids, NSAIDs), consider palliative RT (8 Gy single fraction), optimize systemic therapy
• Key point: Spinal cord compression is oncologic EMERGENCY - median time to irreversible paraplegia is 24-48 hours without treatment.

Scenario 4: Abnormal DRE in Asymptomatic Patient

• Presentation: 58-year-old, hard nodule right lobe on health screening DRE, PSA 3.2 ng/mL
• Approach:
  • Hard nodule overrides PSA threshold - indication for further investigation
  • mpMRI (may reveal larger lesion, guide targeted biopsy)
  • Prostate biopsy (MRI-targeted + systematic)
  • "If cancer confirmed: risk stratification, staging, treatment discussion"
• Key point: Palpable abnormality is indication for biopsy regardless of PSA (15% of cancers occur with PSA less than 4 ng/mL).

Red Flag Recognition

Absolute Emergencies - Immediate Action Required:

1. Spinal Cord Compression

   • Features: Back pain + lower limb weakness/sensory change/sphincter dysfunction
   • Action: Dexamethasone 16 mg IV immediately, MRI whole spine within 24 hours, neurosurgery/oncology urgent referral
   • Outcome: Without treatment, 50% paraplegic within 48 hours

2. Acute Urinary Retention

   • Features: Inability to void, suprapubic pain, palpable bladder
   • Action: Catheterization (urethral or suprapubic if urethral fails), post-obstructive diuresis monitoring, urology referral
   • Risk: Bilateral hydronephrosis, renal failure if chronic obstruction

3. Hypercalcemia of Malignancy (rare in prostate cancer, suggests aggressive disease)

   • Features: Confusion, polyuria, constipation, ECG changes
   • Action: IV fluids, bisphosphonates (zoledronic acid 4 mg IV)

4. Pathologic Fracture with Instability

   • Features: Severe pain, deformity, inability to bear weight
   • Action: Immobilization, orthopedic surgery assessment (fixation + cement augmentation), palliative RT

Common Exam Questions

Q1: "A 65-year-old man has PSA 15 ng/mL. What is your approach?"

Model Answer: "I would approach this systematically. First, I'd take a focused history: urinary symptoms, bone pain, family history, medications (5α-reductase inhibitors lower PSA). On examination, I'd perform DRE assessing for nodules or asymmetry, and general examination for metastatic disease signs.

PSA 15 ng/mL is significantly elevated and warrants investigation. I would arrange:

• Multiparametric MRI prostate (pre-biopsy, per EAU guidelines) for PI-RADS scoring
• If PI-RADS 3-5 lesion: MRI-targeted biopsy plus systematic 12-core biopsy
• Staging investigations if cancer confirmed: Gleason score and PSA will guide whether bone scan/CT or PSMA PET needed

This patient likely has intermediate or high-risk disease if cancer confirmed. Management would involve multidisciplinary team discussion and shared decision-making regarding radical prostatectomy, radiotherapy with ADT, or active surveillance only if unexpectedly low-grade disease."

Q2: "What are the treatment options for localized prostate cancer?"

Model Answer: "Treatment depends on risk stratification, life expectancy, and patient preference. The main options are:

1. Active Surveillance - for low-risk disease (Grade Group 1, PSA less than 10, T1-T2a). The ProtecT trial showed no survival difference between monitoring, surgery, and radiotherapy at 10-15 years. Protocol involves PSA every 3-6 months, repeat biopsy at 1-2 years, with triggers for intervention being grade progression or patient preference.

2. Radical Prostatectomy - surgical removal of prostate and seminal vesicles. Robot-assisted laparoscopic approach is commonest. Offers excellent cancer control (over 90% 10-year survival for localized disease) but risks include erectile dysfunction (30-75%), urinary incontinence (5-20% at 1 year), and anastomotic stricture (2-10%).

3. External Beam Radiotherapy - IMRT 74-81 Gy over 7-9 weeks, or hypofractionated regimens. For intermediate/high-risk, combined with ADT 6 months to 2-3 years. Non-inferior to surgery with different side effect profile: rectal bleeding (5-15%), urethral stricture, delayed erectile dysfunction.

4. Brachytherapy - permanent seed implantation (LDR) or high-dose-rate temporary. Best for low/intermediate risk with favorable anatomy (gland less than 60cc, good urinary flow). Excellent biochemical control (85-95% at 10 years for low-risk).

Choice requires shared decision-making discussing oncologic outcomes, side effects, and patient priorities."

Q3: "Describe the management of metastatic hormone-sensitive prostate cancer."

Model Answer: "Metastatic hormone-sensitive prostate cancer, or mHSPC, is newly diagnosed or recurrent metastatic disease that hasn't been treated with continuous ADT. The paradigm has shifted dramatically - ADT monotherapy is NO longer standard of care.

Current standard is combination therapy:

1. ADT plus Docetaxel - CHAARTED trial showed median OS 57.6 vs 44 months, particularly beneficial in high-volume disease (visceral mets or 4+ bone lesions). Docetaxel 75 mg/m² every 3 weeks for 6 cycles.

2. ADT plus Novel AR-Targeted Agent - Options are abiraterone (LATITUDE trial, OS 53 vs 36 months), enzalutamide (ENZAMET trial), or apalutamide (TITAN trial). Better tolerated than chemotherapy, particularly suitable for low-volume or frail patients.

3. ADT plus Radiation to Primary - STAMPEDE showed OS benefit in low-volume disease.

Treatment selection considers disease volume, patient fitness, and preference. High-volume disease often gets docetaxel or AR agent; low-volume may get AR agent or RT. Triplet therapy (ADT + docetaxel + AR agent) is emerging from ARASENS trial with darolutamide.

All patients require bone health optimization, cardiovascular risk assessment, and monitoring for ADT adverse effects including osteoporosis, metabolic syndrome, and cognitive changes."

Q4: "What is the mechanism of castration resistance?"

Model Answer: "Castration-resistant prostate cancer develops despite castrate testosterone levels (less than 50 ng/dL) through multiple mechanisms:

1. AR Amplification - tumor cells produce more androgen receptors to capture residual androgens more efficiently.

2. AR Mutations - point mutations allow promiscuous AR activation by other steroids or even antagonists.

3. AR Splice Variants - particularly AR-V7, which lacks the ligand-binding domain and is constitutively active without testosterone.

4. Intratumoral Androgen Synthesis - tumor cells upregulate enzymes to synthesize testosterone de novo within the tumor microenvironment from cholesterol.

5. Bypass Pathways - activation of alternative signaling (PI3K/AKT, MAPK) circumvents AR dependence.

6. Neuroendocrine Differentiation - lineage plasticity where tumor cells transdifferentiate to AR-independent neuroendocrine phenotype, highly aggressive with poor prognosis.

Clinically, CRPC is defined by PSA progression (25% rise, 2 consecutive rises over nadir) or radiographic progression despite castrate testosterone. Management involves sequential therapies targeting persistent AR signaling (abiraterone, enzalutamide), chemotherapy (docetaxel, cabazitaxel), PARP inhibitors if HRR mutations, radium-223 for bone disease, and Lu-177-PSMA in heavily pretreated patients."

Q5: "What are the complications of androgen deprivation therapy?"

Model Answer: "ADT has multiple significant adverse effects that must be discussed during consent:

Metabolic/Endocrine:

• Metabolic syndrome in 50-60%: weight gain (5-10 kg), insulin resistance, dyslipidemia, increased diabetes risk
• Osteoporosis: 5-10% annual bone mineral density loss, 20-30% fracture risk at 5 years. Requires DEXA screening and bisphosphonate/denosumab treatment if T-score ≤-2.5
• Hot flashes in 60-80%, managed with venlafaxine, gabapentin, or acupuncture

Cardiovascular:

• 20-50% increased risk of myocardial infarction/stroke, particularly with GnRH agonists within first year. GnRH antagonists (relugolix, degarelix) have lower CV risk per HERO trial. Requires cardiovascular risk factor optimization.

Neurocognitive:

• Cognitive impairment in 20-40%, affecting memory and executive function. Monitor and minimize duration if feasible.

Sexual:

• 90% libido loss, 70% erectile dysfunction. PDE5 inhibitors have limited efficacy on ADT.

Hematologic:

• Anemia in 80-90%, usually mild (Hb 11-12 g/dL)

Other:

• Gynecomastia 10-40% (higher with anti-androgens), prevent with prophylactic breast radiation or tamoxifen
• Fatigue 50-70%, encourage exercise

Monitoring requires: testosterone (confirm castrate level), PSA, DEXA, metabolic panel (glucose, lipids), cardiovascular assessment. The goal is to balance cancer control with quality of life, using intermittent ADT when appropriate to minimize toxicity."

Viva Points

Opening Statement for Prostate Cancer: "Prostate cancer is the most common non-cutaneous malignancy in men, with approximately 1.4 million cases annually worldwide. It arises from glandular epithelium, predominantly in the peripheral zone, with a highly variable natural history from indolent disease amenable to surveillance to aggressive metastatic cancer requiring intensive combination therapy. The Gleason grading system, now reported as ISUP Grade Groups 1-5, combined with PSA and TNM stage, stratifies patients into risk categories guiding management from active surveillance to multimodal therapy."

Key Statistics to Quote:

• Lifetime risk: 1 in 8 men (high-income countries)
• Median age at diagnosis: 66 years
• 5-year survival: 98-100% localized, 30-35% metastatic
• BRCA2 mutation: 8.6-fold risk increase
• PSA screening: 20-30% mortality reduction, NNS ~1000 to prevent 1 death
• Active surveillance: 98% cancer-specific survival at 10-15 years for low-risk disease

Classifications to Know:

• ISUP Grade Groups (1-5)
• TNM 8th edition staging
• NCCN Risk Groups (Very Low, Low, Favorable/Unfavorable Intermediate, High, Very High)
• D'Amico classification (historical reference)
• Disease states: localized, locally advanced, mHSPC, nmCRPC, mCRPC

Landmark Trials - Be Ready to Cite:

• ProtecT (2016): Monitoring vs surgery vs RT for localized disease - no survival difference at 15 years [PMID: 27626136]
• CHAARTED (2015/2018): ADT + docetaxel improved OS by 13.6 months in mHSPC [PMID: 29384722]
• STAMPEDE (2022): Abiraterone or docetaxel added to ADT improved OS in high-risk/metastatic disease [PMID: 34953525]
• LATITUDE (2017): Abiraterone + ADT: 3-year OS 66% vs 49% in high-risk mHSPC [PMID: 28578639]
• PROfound (2020): Olaparib improved rPFS in BRCA1/2-mutated mCRPC [PMID: 32343890]
• VISION (2021): Lu-177-PSMA improved OS 15.3 vs 11.3 months in heavily-treated mCRPC [PMID: 34161051]

Common Examiner Questions:

1. "When would you use active surveillance?" → Low-risk disease, life expectancy consideration, informed patient choice, protocol requirements
2. "Difference between GG2 and GG3?" → 3+4=7 (GG2, majority pattern 3) vs 4+3=7 (GG3, majority pattern 4) - significantly different prognosis
3. "How do you manage biochemical recurrence post-prostatectomy?" → PSA ≥0.2 ng/mL on 2 occasions. Assess: PSADT (less than 3 months high-risk), time to recurrence, Gleason score. Options: salvage RT (if PSA less than 0.5-1.0, better outcomes), ADT, observation. Imaging: PSMA PET to exclude distant disease.
4. "What is the role of PSMA PET?" → Superior to conventional imaging for staging and recurrence detection. Changes management in 15-30%. Detection rate PSA-dependent: 33% at 0.2-0.5, over 95% at over 2 ng/mL. Guides salvage therapy localization.

Common Mistakes (Avoid These!)

❌ Mistake: Quoting Gleason score without Grade Group conversion
✅ Correct: Use ISUP Grade Groups (contemporary standard since 2014)

❌ Mistake: Offering ADT monotherapy for mHSPC
✅ Correct: Combination therapy is standard (ADT + docetaxel OR ADT + AR agent)

❌ Mistake: Forgetting to assess life expectancy before recommending aggressive local therapy
✅ Correct: Radical therapy only beneficial if greater than 10-year life expectancy

❌ Mistake: Missing spinal cord compression red flags
✅ Correct: Back pain + ANY neurological symptoms = urgent MRI and dexamethasone

❌ Mistake: Stating PSA is "cancer-specific"
✅ Correct: PSA is prostate-specific, NOT cancer-specific (elevated in BPH, prostatitis)

❌ Mistake: Recommending brachytherapy for high-risk disease without EBRT
✅ Correct: Brachytherapy monotherapy only for low/favorable intermediate risk; high-risk needs EBRT + ADT

❌ Mistake: Ignoring ADT adverse effects
✅ Correct: Counsel on osteoporosis, cardiovascular risk, metabolic syndrome, sexual dysfunction - proactive management required